Clinical Scenario

This protocol applies to patients with Glycogen storage disease type IV who also have neurogenic bladder. The presenting symptom cluster — urinary urgency, urinary frequency, nocturia, and urinary incontinence — defines the management pathway and requires a structured, stepwise approach.

Treatment Approach

Management follows a stepwise escalation. The initial phase centres on behavioral and conservative measures — adjustments to fluid intake, voiding habits, and pelvic floor function — before advancing to pharmacologic options.

For patients who do not achieve adequate control with earlier lines, interventional procedures targeting the bladder or peripheral nerve pathways represent the next step.

The full protocol specifies the complete sequence, eligibility criteria, and decision points — available via the link below.

References

For patients with urgency, frequency, nocturia, and incontinence first-line treatment includes behavioral modifications such as fluid modulation (or restriction prior to going to bed), elimination of bladder irritants (e.g., caffeine, alcohol), timed voiding (i.e., voiding before urgency or incontinence typically occurs) and optimizing bowel function as well as pelvic floor muscle exercises.
Second-line treatment includes bladder control medications (e.g., antimuscarinics, β3-agonists); third-line treatment includes botulinum toxin injection into the bladder and neuromodulation of the sacral or tibial nerves.

DOI: 10.1016/j.ymgme.2023.107525

View source ↗

Treatment of Glycogen Storage Disease Type IV in Neurogenic Bladder with Urinary Urgency, Frequency, and Incontinence

Clinical Scenario

Treatment Approach

References